Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

NCT02195973 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

DRUG: LDE225

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]